<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This multicentre, double-blind, placebo-controlled study investigated the efficacy of <z:chebi fb="0" ids="2376">acarbose</z:chebi> in Chinese individuals with <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (determined using a 75 g oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test) </plain></SENT>
<SENT sid="1" pm="."><plain>Subjects were randomised to either placebo or <z:chebi fb="0" ids="2376">acarbose</z:chebi> 50 mg t.i.d. for a period of 16 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>Primary efficacy variables were the maximum postprandial plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> value (C(max)) and the serum insulin profile </plain></SENT>
<SENT sid="3" pm="."><plain>Secondary efficacy parameters included postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> profile, maximum postprandial insulin concentration (C(max)), changes in <z:chebi fb="23" ids="18059">lipid</z:chebi> profile and blood pressure and HbA(1c) and body weight and conversion to Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>In the intention-to-treat analysis, <z:chebi fb="0" ids="2376">acarbose</z:chebi> treatment resulted in significantly higher reductions in postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> and serum insulin concentrations compared to placebo </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="17855">Triglyceride</z:chebi> concentration was the only <z:chebi fb="23" ids="18059">lipid</z:chebi> parameter to be significantly reduced in <z:chebi fb="0" ids="2376">acarbose</z:chebi> subjects </plain></SENT>
<SENT sid="6" pm="."><plain>Loss of body weight was also significantly greater for <z:chebi fb="0" ids="2376">acarbose</z:chebi> than placebo subjects </plain></SENT>
<SENT sid="7" pm="."><plain>Some 19 individuals converted to Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (seven <z:chebi fb="0" ids="2376">acarbose</z:chebi>, 12 placebo), but this difference was not significant </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="2376">Acarbose</z:chebi> is efficacious in improving the metabolic state of individuals with <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> indicating a potential benefit for the delay or prevention of <z:hpo ids='HP_0003674'>onset</z:hpo> of Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in Chinese subjects </plain></SENT>
</text></document>